Anzeige
Mehr »
Login
Mittwoch, 28.02.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
Nurexone Biologic: Prof. Levenberg erklärt, wie die ExoTherapy funktioniert!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTV | ISIN: NL0010696654 | Ticker-Symbol: UQ1
Tradegate
27.02.24
21:21 Uhr
6,160 Euro
-0,050
-0,81 %
1-Jahres-Chart
UNIQURE NV Chart 1 Jahr
5-Tage-Chart
UNIQURE NV 5-Tage-Chart
RealtimeGeldBriefZeit
6,0806,26027.02.
6,1006,28027.02.

Aktuelle News zur UNIQURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.12.23Benefit of uniQure's Huntington's gene therapy will be revealed 'in the fullness of time'19
19.12.23UniQure climbs after trial results for genetic disorder treatment12
19.12.23uniQure N.V. - 8-K, Current Report1
19.12.23uniQure Inc.: uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease522~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history...
► Artikel lesen
08.12.23uniQure N.V. - S-8, Securities to be offered to employees in employee benefit plans2
08.12.23uniQure Inc.: uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)333LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement...
► Artikel lesen
29.11.23UniQure Says FDA Clears IND Application For AMT-191 Gene Therapy For Fabry Disease7
29.11.23uniQure wins FDA nod to study gene therapy for Fabry disease4
29.11.23uniQure Inc.: uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease330Patient enrollment expected to begin in first half of 2024LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023N.V.. AMT-191 comprises an AAV5 vector that delivers an a-galactosidase A (GLA) transgene designed...
► Artikel lesen
17.11.23uniQure N.V. - 8-K, Current Report3
07.11.23Uniqure NV reports results for the quarter ended in September - Earnings Summary7
07.11.23uniQure N.V. - 10-Q, Quarterly Report1
07.11.23uniQure N.V. - 8-K, Current Report2
07.11.23uniQure Inc.: uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress335~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase...
► Artikel lesen
24.10.23uniQure Inc.: uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting518LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023(NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations...
► Artikel lesen
06.10.23uniQure (QURE) Up on Restructuring Plans, Workforce Reduction5
06.10.23uniQure sheds a fifth of its staff and half its R&D3
05.10.23uniQure N.V. - 8-K, Current Report2
05.10.23Why Shares of uniQure Are Up Thursday4
05.10.23uniQure offloads 5th of staff, half of R&D projects to keep gene therapies in clinic into 20272
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1